Antibodies
RGD (Arg-Gly-Asp) Peptides
- 貨號 Cat. No.
- S8008
- 規格 Size
- 10mg
- 品牌 Brand
- Selleckchem
Description
RGD (Arg-Gly-Asp) Peptides
Catalog No.S8008
RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins.
| Size | Price | Stock | Quantity | ||||
|---|---|---|---|---|---|---|---|
| |||||||
Distributor Tel: +886-2-2827-1197jimmy@new.abscience.com.tw
Biological Activity
| Description | RGD (Arg-Gly-Asp) Peptides is a cell adhesion motif which can mimic cell adhesion proteins and bind to integrins. | |||||
|---|---|---|---|---|---|---|
| Targets | ||||||
| IC50 | ||||||
| In vitro | The RGD sequence is the cell attachment site of a large number of adhesive extracellular matrix, blood, and cell surface proteins, and nearly half of the over 20 known integrins recognize this sequence in their adhesion protein ligands. The RGD peptides and mimics can be used to probe integrin functions in various biological systems. Drug design based on the RGD structure may provide new treatments for diseases such as thrombosis, osteoporosis, and cancer. [1] RGD peptide acts as an inhibitor of integrin-ligand interactions and can induce apoptosis in the absence of signals and integrin-mediated cell clustering. Research demonstrates that RGD peptides promote apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. [2] The RGD peptide can serve as a cell adhesion site of extracellular matrix, cell surface proteins, and integrins. [3] In addition, RGD peptide can inhibit ACK-2 activation through cell adhesion.[4] | |||||
| In vivo | ||||||
| Features | ||||||
Protocol(Only for Reference)
References
Clinical Trial Information( data from http://clinicaltrials.gov)
| NCT Number | Recruitment | Conditions | Sponsor /Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT00364728 | Recruiting | SLE|Rheumatoid Arthritis|Healthy Subjects | National Taiwan University Hospital | 2006-01 | |
| NCT00565721 | Completed | High-grade Glioma|Lung Cancer|Head & Neck Cancer|Sarcoma|Melanoma | GE Healthcare | 2007-11 | |
| NCT01176500 | Withdrawn | Colon Cancer|Lung Cancer|Cervical Cancer|Renal Cell Carcinoma|Uterine Cancer | National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI)|GE Healthcare | 2010-07 | Phase 1|Phase 2 |
| NCT01806675 | Recruiting | Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Male Breast Cancer|Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Adenoid Cystic Carcinoma of the Oral Cavity etc. | Stanford University|National Cancer Institute (NCI) | 2013-03 | Phase 1|Phase 2 |
| NCT01492192 | Not yet recruiting | Carcinoma, Renal Cell | Oxford University Hospitals NHS Trust|GE Healthcare|University of Oxford | 2013-04 | Phase 2 |
Chemical Information
Download RGD (Arg-Gly-Asp) Peptides SDF
| Molecular Weight (MW) | 346.34 |
|---|---|
| Formula | C12H22N6O6 |
| CAS No. | 99896-85-2 |
| Storage | 3 years -20℃Powder |
|---|---|
| 6 months-80℃in DMSO | |
| Syonnyms | Arginine-Glycine-Aspartic Acid |
| Solubility (25°C) * | In vitro | DMSO | <1 mg/mL (<1 mM) |
|---|---|---|---|
| Water | 12 mg/mL (34 mM) | ||
| Ethanol | <1 mg/mL (<1 mM) | ||
| * <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. | |||
| Chemical Name | L-Aspartic acid, L-arginylglycyl- |
|---|
Preparing Stock Solutions
| Stock Solution (1ml DMSO) | 1mM | 10mM | 20mM | 30mM |
|---|---|---|---|---|
| Mass(mg) | 0.34634 | 3.4634 | 6.9268 | 10.3902 |
